Business Context and Reporting Period
This Form 8-K filing by Lucid Diagnostics Inc. (LUCD) reports a corporate governance event dated March 18, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York. The filing specifically addresses the appointment of a new senior executive and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- Base Salary: $150,000 annually for the new Chief Operating Officer.
- Performance Bonus: Up to 50% of the base salary, subject to Board discretion.
- Contract Term: Initial term expires February 22, 2025, with automatic one-year renewals.
Material Changes
The primary material change reported is the appointment of Shaun O'Neil as Chief Operating Officer and Executive Vice President, effective March 18, 2022. Mr. O'Neil previously served as the Company's Chief Commercial Officer since July 2018. Additionally, he has served as the Chief Operating Officer of PAVmed Inc., the majority shareholder of Lucid Diagnostics, since February 2022.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. However, it outlines specific contractual risks and contingencies regarding the new executive agreement:
- Termination Provisions: The Company may terminate employment with "cause" or without cause upon 30 days' notice. Mr. O'Neil may terminate with "good reason" or without good reason upon 30 days' notice.
- Severance Contingencies: In the event of termination without cause or resignation with good reason, Mr. O'Neil is entitled to 12 months of base salary, a pro rata bonus, and 12 months of health insurance coverage.
- Non-Compete Restrictions: The agreement includes non-compete clauses restricting Mr. O'Neil from competing with the Company for one year post-employment (or two years in the event of a change of control).
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Confirm the ownership structure and relationship between Lucid Diagnostics and PAVmed Inc.
- Review subsequent filings for any changes to the executive team or compensation structure.
- Note that this filing provides no update on the Company's clinical trial progress or product commercialization status.